ZINC ADJUVANT TREATMENT IN SARS-COV-2: A RANDOMIZED CLINICAL TRIAL
Silvia Gómez-Zorrilla, Elena Sendra, Juan Du, Mercé Espona, Alejandro Fierro- Villegas, Ana Siverio, Alicia Rodriguez-Alarcón, Silvia Castañeda, Inmaculada Lopez Montesinos, Cristina Plata, Itziar Arrieta-Aldea, Jade Soldado-Folgado, Natalia García-Giralt, Rubén Vicente, Robert Güerri-Fernández
doi:10.22541/au.174532324.40343996/v1
Introduction: Zinc plays a key role in immune function and has demonstrated antiviral and anti-inflammatory properties. Low plasma zinc levels have been associated with poor outcomes in COVID-19. This study aims to evaluate the efficacy and safety of zinc supplementation as an adjuvant therapy in hospitalized patients with COVID-19. Methods: A single-center, randomized, open-label clinical trial between May and December 2021. Adults hospitalized with confirmed COVID-19 requiring hospitalization were randomized 1:1 to receive standard of care (SoC) with or without oral zinc acetate (90 mg/day) for 14 days. The primary endpoint was disease progression, defined as critical care requirement (ICU admission) or death. Secondary outcomes included time to clinical recovery, hospital length of stay, WHO clinical scale improvement, inflammatory markers, antibody response, and safety. Results: Seventy-one patients were randomized (35 zinc vs 34 SoC). Disease progression occurred in 5.7% of the zinc group vs. 23.5% in the SoC group (OR 0.21, 95%CI=0.03-0.96,). Mean recovery time was significantly shorter in the zinc group (7.4 ± 6.1 vs. 13.1 ± 9.7 days, p=0.006) and a trend to a faster recovery was observed in the Cox proportional hazards model in the intervention group HR of 1.670 (95% CI: 0.948-2.942), p = 0.076. WHO scale improvement attaining a <1 points at day 14 was greater in the zinc group (74.3% vs. 42.4%, p=0.009). Antibody levels were higher in the SoC group at days 14 and 28. No adverse events were attributed to zinc. Conclusions: Adjunctive Zinc supplementation to standard of care reduced disease progression and showed a trend to accelerated clinical recovery in hospitalized COVID-19 patients, supporting its potential role in managing viral respiratory infections.
Intervention (yellow line) groups.
References
Abdallah, Mhalla, Trabelsi, Sekma, Youssef et al., Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial, Clin Infect Dis
Badriyah, Briggs, Meredith, Jarvis, Schmidt et al., Decision-tree early warning score (DTEWS) validates the design of the National Early Warning Score (NEWS), Resuscitation
Baiocchi, Vojdani, Rosenberg, Vojdani, Halpert et al., Cross-sectional analysis reveals autoantibody signatures associated with COVID-19 severity, J Med Virol
Chen, Lu, Churov, Fu, Research Progress on NK Cell Receptors and Their Signaling Pathways, Mediators Inflamm
Gammoh, Rink, Zinc in Infection and Inflammation, Nutrients
Hemilä, Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage, JRSM Open
Hunter, Arentz, Goldenberg, Yang, Beardsley et al., Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials, BMJ Open
Li, Luo, Liang, Circulating trace elements status in COVID-19 disease: A meta-analysis, Front Nutr
Prasad, Discovery of human zinc deficiency: its impact on human health and disease, Adv Nutr Bethesda Md
Read, Obeid, Ahlenstiel, Ahlenstiel, The Role of Zinc in Antiviral Immunity, Adv Nutr
Rheingold, Raval, Gordon, Hardigan, Zinc Supplementation Associated With a Decrease in Mortality in COVID-19 Patients: A Meta-Analysis, Cureus
Schulz, Altman, Moher, Group, CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials, BMJ
Vogel-González, Talló-Parra, Herrera-Fernández, Pérez-Vilaró, Chillón et al., Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection, Nutrients
Xu, Liu, Zou, Luo, Wu et al., Hypozincemia in COVID-19 Patients Correlates With Stronger Antibody Response, Front Immunol
DOI record:
{
"DOI": "10.22541/au.174532324.40343996/v1",
"URL": "http://dx.doi.org/10.22541/au.174532324.40343996/v1",
"accepted": {
"date-parts": [
[
2025,
4,
22
]
]
},
"author": [
{
"ORCID": "https://orcid.org/0000-0002-5987-068X",
"affiliation": [
{
"name": "Hospital del Mar"
}
],
"authenticated-orcid": true,
"family": "GÓMEZ-ZORRILLA",
"given": "SILVIA",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Hospital del Mar"
}
],
"family": "Sendra",
"given": "Elena",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Hospital del Mar"
}
],
"family": "Du",
"given": "Juan",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Hospital del Mar"
}
],
"family": "Espona",
"given": "Mercé",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Universitat Pompeu Fabra"
}
],
"family": "Villegas",
"given": "Alejandro Fierro-",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Laboratori de Referencia de Catalunya SA"
}
],
"family": "Siverio",
"given": "Ana",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Hospital del Mar"
}
],
"family": "Rodriguez-Alarcón",
"given": "Alicia",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Hospital del Mar"
}
],
"family": "Castañeda",
"given": "Silvia",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Hospital del Mar"
}
],
"family": "Montesinos",
"given": "Inmaculada Lopez",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Universitat Pompeu Fabra"
}
],
"family": "Plata",
"given": "Cristina",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Hospital del Mar"
}
],
"family": "Arrieta-Aldea",
"given": "Itziar",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Hospital del Mar"
}
],
"family": "Soldado-Folgado",
"given": "Jade",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Hospital del Mar"
}
],
"family": "García-Giralt",
"given": "Natalia",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Universitat Pompeu Fabra"
}
],
"family": "Vicente",
"given": "Rubén",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Hospital del Mar"
}
],
"family": "Güerri-Fernández",
"given": "Robert",
"sequence": "additional"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2025,
4,
22
]
],
"date-time": "2025-04-22T12:00:48Z",
"timestamp": 1745323248000
},
"deposited": {
"date-parts": [
[
2025,
4,
22
]
],
"date-time": "2025-04-22T12:00:48Z",
"timestamp": 1745323248000
},
"group-title": "Preprints",
"indexed": {
"date-parts": [
[
2025,
4,
22
]
],
"date-time": "2025-04-22T12:40:10Z",
"timestamp": 1745325610685,
"version": "3.40.4"
},
"institution": [
{
"name": "Authorea Inc."
}
],
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2025,
4,
22
]
]
},
"member": "9829",
"original-title": [],
"posted": {
"date-parts": [
[
2025,
4,
22
]
]
},
"prefix": "10.22541",
"published": {
"date-parts": [
[
2025,
4,
22
]
]
},
"publisher": "Authorea, Inc.",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.authorea.com/users/916055/articles/1288904-zinc-adjuvant-treatment-in-sars-cov-2-a-randomized-clinical-trial?commit=53189f422df29d63308563c2be213a77b6699dc2"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"subtype": "preprint",
"title": "ZINC ADJUVANT TREATMENT IN SARS-COV-2: A RANDOMIZED CLINICAL TRIAL",
"type": "posted-content"
}
